@TiffStevensMD
The sexiest survival curve at #ASCO26 by far: updated 7-year PFS from the ITT population of #lorlatinib in the #CROWN trial for ALK+ #lungcancer, presented by @TonyMok9.
Longest duration of response yet seen with targeted therapy in #lungcancer: median PFS still not reached at 7 years.
55% vs 3% for crizotinib (HR 0.19).
➡️ looking forward to see what the next generation of ALK inhibitors will bring in terms of efficacy and improved toxicity profile
@ALKPositiveincView quoted post on X
Dr. @FSkoulidis presents randomized phase 2b TRITON study at #ASCO26: chemo + durvalumab + tremelimumab vs chemo + pembro in non-squamous NSCLC with STK11, KEAP1, and/or KRAS mutations. RR numerically favors dual checkpoint in the challenging STK11 and KRAS subsets. PFS pending.View quoted post on X
🚨 #ASCO26 | WU-KONG28 Sunvozertinib vs platinum-based chemotherapy 1L advanced NSCLC with EGFR exon20ins #️⃣Abstr 8500
🔥Simultaneously published in NEJM
nejm.org/doi/full/10.10…
✅ Primary endpoint met: ・mPFS 10.3 vs 7.5 mo ・HR 0.65, P=0.0008
🎯 Tumor response: ・cORR 58.9% vs 31.1% ・DCR 94.5% vs 85.7% ・DoR 11.2 vs 7.1 mo
⏭️ PFS2: ・21.7 vs 15.5 mo ・HR 0.70
⚖️ Manageable safety Common TRAEs were consistent with EGFR inhibition
👉 A potential first-line, single-agent oral targeted therapy for EGFR exon20ins NSCLC.View quoted post on X
OptiTROP-Lung05 is clearly pos but interpretation is challenging because pembrolizumab monotherapy is not the most relevant standard for PD-L1 1–49% disease. the benefit seen in PD-L1 ≥50% supports genuine efficacy of sac-TMT + pembrolizumab beyond IO alone #ASCO26 @OncoAlertView quoted post on X
“No single framework speaks for all.” Great #ASCO26 talk by #IsaiahMacDonald on cancer care for sexual & gender minority patients. Individualized cancer screening, treatment & survivorship approaches are needed. Inclusive oncology is better oncology 🏳️🌈🏳️⚧️ @ASCO #LGBTQHealthView quoted post on X
